| nivolumab based treatment | pembrolizumab based treatment |
| nivolumab alone | pembrolizumab alone |
| mML - (neo)adjuvant (NA) | | |
| mML - NA - all population 9 | | |
| mML - NA - PDL1 positive 1 | | |
Comparator:
vs Ipilimumab (10 mg/kg); vs placebo;
Risk of bias:
low;
some concerns;
high;
NA;